RxDoctor Payments Data

Stefanie Thomas, DPM

Podiatrist · Clinton, MSNPI 1497864698

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Organogenesis Inc. at 41.4% of the total. Reporting peaked in 2023 at $640 and has fallen 88.0% since, to $77 in 2025.

$1,603in general payments, 2019–2025

Across 53 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$664
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$262
  • Kerecis Limited$207
  • Convatec Inc.$152
  • Paratek Pharmaceuticals, Inc.$103
  • Amgen$50
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$1,603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,603 in reported general payments places this provider in the 70th percentile of 28 podiatrist providers in Mississippi.

See all podiatrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,049,914
Medicare patients
727
Services billed
3,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole35$28,634
Itraconazole44$4,258
Terbinafine Hcl218$3,313
Vancomycin Hcl30$2,809
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc19$1,506
Pregabalin41$1,443
Gabapentin82$1,030
Gentamicin Sulfate22$955
Mupirocin70$514
Diclofenac Sodium36$509
Ammonium Lactate17$331
Allopurinol36$276
Methylprednisolone34$203
Ciprofloxacin Hcl20$161
Meloxicam48$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$262$28,63435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 podiatrist providers in Mississippi.

Other podiatrist in Clinton

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →